Kevin Hackshaw is a Rheumatology/Immunology physician affiliated with The University of Texas at Austin. OpenAlex indexes 86 publications with 2,188 citations (h-index 26).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
38.7%Gabapentinoids14.1%Pregabalin54%Gabapentin32%Horizant15%Part D<11 patientsTricyclic Antidepressant10.3%Nortriptyline Hcl100%Part D≥29 patients+ 5 more classes in this area
Cancer & immunology
25.6%Folate Analog Metabolic Inhibitor10.7%Methotrexate100%Part D≥29 patientsTNF inhibitor8.6%Humira(Cf) Pen62%Humira Pen15%Enbrel Sureclick12%Cimzia11%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
19.1%Corticosteroid16.7%Prednisone100%Part D≥42 patientsAminosalicylate1.5%Sulfasalazine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:
- Objective tests utilizing Vibrational Spectroscopy for Diagnosis and Severity of Fibromyalgia and Related Pain Syndromes
University of Texas at Austin
FY2025$569,451R33NS117211 - Objective tests utilizing Vibrational Spectroscopy for Diagnosis and Severity of Fibromyalgia and Related Pain Syndromes
University of Texas at Austin
FY2024$557,573R33NS117211 - Objective tests utilizing Vibrational Spectroscopy for Diagnosis and Severity of Fibromyalgia and Related Pain Syndromes
University of Texas at Austin
FY2020$1,466,498R61NS117211
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early diagnostics of fibromyalgia: an overview of the challenges and opportunities
Expert Review of Molecular Diagnostics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Warach, MD
The University of Texas at Austin
William Streusand, MD
The University of Texas at Austin
Matthew Padrick, MD
The University of Texas at Austin
Elizabeth Matsui, MD
The University of Texas at Austin
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”